Executive Summary of the 2020 Clinical Practice Guidelines for the Management of Dyslipidemia in the Philippines
Journal of the ASEAN Federation of Endocrine Societies
Dyslipidemia is a cardiovascular risk factor that is increasing in prevalence in the country. The need to treat and manage elevated cholesterol levels, both pharmacologic and non-pharmacologic, is of utmost importance. Different medical societies and groups bonded together to formulate the 2020 Philippine Clinical Practice Guidelines for dyslipidemia. The group raised nine clinical questions that are important in dyslipidemia management. A technical working group analyzed the clinical questions dealing with non-pharmacologic management, primary prevention for both non-diabetic and individuals with diabetes, familial hypercholesterolemia, secondary prevention, adverse events of statins and the use of other lipid parameters as measurement of risk for cardiovascular disease. Randomized controlled trials and meta-analyses were included in the GRADE-PRO analysis to come up with the statements answering the clinical questions. The statements were presented to a panel consisting of government agencies, members of the different medical societies, and private institutions, and the statements were voted upon to come up with the final statements of the 2020 practice guidelines. The 2020 CPG is aimed for the Filipino physician to confidently care for the individual with dyslipidemia and eventually, lower his risk for cardiovascular disease.
Gonzalez-Santos, L., Oliva, R., Jimeno, C., Gonzales, E., Balabagno, M., Ona, D., Cinco, J., Baston, A., Caole-Ang, I., Fojas, M., Hernandez, R., Macrohon-Valdez, M., Rosqueta, M., Punzalan, F., & Llanes, E. (2021). Executive Summary of the 2020 Clinical Practice Guidelines for the Management of Dyslipidemia in the Philippines. Journal of the ASEAN Federation of Endocrine Societies, 36(1), 5-11. https://doi.org/10.15605/jafes.036.01.01